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ABSTRACT
Identification of novel anticancer drugs presenting more than one molecular 
target and efficacy against cancer stem-like cells (CSCs) subpopulations represents 
a therapeutic need to combat the resistance and the high risk of relapse in 
patients. In the present work we show how Bozepinib [(RS)-2,6-dichloro-9-[1-(p-
nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]-9H-purine], a 
small anti-tumor compound, demonstrated selectivity on cancer cells and showed 
an inhibitory effect over kinases involved in carcinogenesis, proliferation and 
angiogenesis. The cytotoxic effects of Bozepinib were observed in both breast and 
colon cancer cells expressing different receptor patterns. Bozepinib inhibited HER-2 
signaling pathway and JNK and ERKs kinases. In addition, Bozepinib has an inhibitory 
effect on AKT and VEGF together with anti-angiogenic and anti-migratory activities. 
Moreover, the modulation of pathways involved in tumorigenesis by Bozepinib was 
also evident in microarrays analysis. Interestingly, Bozepinib inhibited both mamo- 
and colono-spheres formation and eliminated ALDH+ CSCs subpopulations at a low 
micromolar range similar to Salinomycin. Bozepinib induced the down-regulation of 
c-MYC, β-CATENIN and SOX2 proteins and the up-regulation of the GLI-3 hedgehog-
signaling repressor. Finally, Bozepinib shows in vivo anti-tumor and anti-metastatic 
efficacy in xenotransplanted nude mice without presenting sub-acute toxicity. These 
findings support further studies on the therapeutic potential of Bozepinib in cancer 
patients. 
INTRODUCTION
Cancer represents the second cause of death 
by disease in the world, being colorectal and breast 
cancer two diseases with important incidence in most 
countries [1]. Some of the main signaling pathways 
involved in cancer are related with cell proliferation, 
differentiation and survival, which represent exciting 
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targets for developing new anti-tumor drugs. In this 
way, the epidermal growth factor receptors EGFR and 
HER2 are frequently over-expressed in several human 
cancers of epithelial origin and play essential roles in the 
development and progression of cancer [2, 3]. HER2 is 
over-expressed in several tumors, including breast and 
colorectal cancers [4]. In normal cells, the HER proteins 
regulate cell growth, survival, adhesion, migration and 
differentiation through a network of signaling pathways. 
The over-expression of this receptor in breast cancer is 
often associated with increased disease recurrence and a 
worse prognosis. Moreover, in patients where hormonal 
therapy is not effective, HER2 becomes a critical target 
for treatment [5]. Since signal transduction networks 
integrate multiple upstream inputs, targeting pathways 
downstream of the receptors could conceivably result 
in greater therapeutic efficacy and broader applicability. 
Moreover, kinase inhibitors that reduce the excessive 
proliferation signaling are revealed as one of the most 
important emergent therapies against cancer [6]. For this 
reason, kinome profiling has arisen as an important tool to 
develop targeted therapies against kinases with aberrant 
expression directly involved in cancer pathology [7].
The mortality rate of breast and colorectal cancer 
is high because of disease recurrence, which remains the 
major therapeutic barrier in these types of cancer. Although 
chemotherapy or radiotherapy can kill most bulky tumor 
cells and provide temporary remission, relapse occurs in 
most cases, as explained in the recently proposed cancer 
stem cell hypothesis [8, 9]. This hypothesis implies that a 
subset of tumor cells has the ability to self-renew and is 
the source of tumor initiation, progression and recurrence. 
These cancer stem-like cells (CSCs) may also contribute 
to tumor formation, metastasis, and treatment resistance. 
It has been found that multiple stem cell-related molecules 
and enzymatic activities are highly expressed in breast 
and colon CSCs, including c-MYC [10, 11], β-CATENIN 
[12, 13], SOX-2 [14, 15], ALDH1 activity [16], among 
others. Targeting pathways or molecules up-regulated in 
differentiated cancer cells and/or in CSCs populations but 
not in normal cells can provide new strategies for selective 
therapy. 
Recently, our group has reported the synthesis 
and anticancer activities of new (RS)-4,1-benzoxazepin-
purines against human breast and colon cancer cell lines 
[17]. The most active compound (RS)-2,6-dichloro-
9-[1-(p-nitrobenzenesulfonyl)-1,2,3,5-tetrahydro-4,1-
benzoxazepin-3-yl]-9H-purine, named as Bozepinib, 
presents very low inhibitory concentration 50 (IC50) values 
in both breast and colon cancer cells, being the most 
potent structure that we have reported [17, 18]. Bozepinib 
induces the cell death of cancer cells by apoptosis also 
triggering other interesting anti-tumor activities such 
as autophagy and senescence processes in cancer cells 
without inducing acute toxicity in mice [17, 18]. These 
effects make Bozepinib a very attractive anti-tumor 
agent, opening a new strategy in cancer chemotherapy 
with future clinical application in cancer. The aim of this 
work was to characterize the mechanism of action of 
this drug analyzing its effect over kinases, receptors and 
signaling pathways that are targets for new promising 
therapies. In addition, we evaluated its effect on enriched 
subpopulations of CSCs and in related proteins of CSCs 
pathways. Finally, we studied the in vivo anti-tumor 
activity of Bozepinib using xenograft transplants of breast 
and colon cancer.
RESULTS
Bozepinib has an antiproliferative and selective 
effect on breast and colon cancer cell lines
We have previously described the anti-tumor 
effect of Bozepinib in some breast and colon cancer cell 
lines [17, 18]. To test the selective action of Bozepinib 
against breast and colon cancer cells we determined the 
therapeutic index (TI). As shown in Table 1, the IC50 value 
of CCD-18Co, a non-tumor colon cell line, was almost 
double that in T84 and HT29 colon tumor cells and more 
than triple for Caco-2 and SW-480 colon cancer cell lines, 
showing a TI close to 9 for the SW-480 cell line. Better 
results were obtained in breast cancer cell lines where 
the IC50 values determined for the MCF-10A non-tumor 
cell line were more than five times higher that the IC50 
determined for MCF-7 and SKBR-3 breast cancer cell 
lines and almost double that of the value determined for 
MDA-MB 468 cancer cells, presenting the MDA-MB 231 
a TI equal to 11 (Table 1). These values confirm the potent 
anti-tumor effects of the drug and its selective cancer 
activity.
HER2 signaling pathway and several proliferative 
kinases are inhibited by Bozepinib 
To study the effect of Bozepinib on cancer 
proliferation pathways, we carried out an ex vivo 
multikinase screening assay (n=36) using 5µM and 50µM 
(Supplementary Table S3). Bozepinib treatment at 50µM 
showed a significant inhibitory effect over numerous 
kinases such as JNK and ERKs, inhibiting also the EGFR 
and HER2 cellular signaling pathways. In fact, HER2, 
AKT2 and VEGF receptors were considerably inhibited 
in the screening (Supplementary Table S3). In order to 
analyze whether Bozepinib inhibits the HER2 signaling 
pathways in breast cancer cells, we treated the HER2 
positive SKBR-3 cell line with 5 µM of Bozepinib and we 
analyzed the expression and activation of proteins involved 
in HER2 signaling at different times post-treatment by 
western blot analysis (Fig. 1A). Whereas the total level 
of HER2 receptor remained stable during treatment, the 
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phophorylated form was completely inhibited after 2 hours 
post-treatment. Consequently, p-AKT was also inhibited 
and accompanied with a significant decrease in the total 
level of VEGF (Fig. 1A). Moreover, we also detected 
both the inhibition of ERKs and JNK phosphorylation in 
MCF-7 and MDA-MB 468 breast cancer cell lines, that 
was more notable in MCF-7 cells at 4 hours post-treatment 
and in MDA-MB 468 cell line after 8 hours post-treatment 
(Fig. 1B and 1C). Whereas phosphorylation of JNK was 
not detectable in normal MCF-10A mammary epithelial 
cells as previously described [19], the phosporylation of 
ERKs was weakly up-regulated at 8 hours post-treatment 
and was similar to the control non-treated cells at 16 hours 
post-treatment (Fig. 1D).
Bozepinib has antiangiogenic properties and 
inhibits cell migration
The ability of Bozepinib to suppress capillary-
like structures was assessed by culturing HUVEC 
endothelial cells on MATRIGELTM-coated wells. As 
shown in Fig. 2A, HUVEC were able to form capillary-
like structures. However, Bozepinib was enough to inhibit 
the development of these capillary-like structures in a 
dose-dependent manner after 4 and 8h of treatment (Fig. 
2A). As shown in Fig. 2B, the HUVECs viability was 
maintained throughout 4 and 8 hours of treatment with 
low doses of Bozepinib (0,01 µM and 0,1 µM). At 4 and 
8 hours the treatment with 5µM of Bozepinib presented a 
percentage of viability around 80% whereas the induction 
of apoptosis was detected only at 8 hours post-treatment 
showing an increase of just 15% compared to control 
cells. However, the vessel-like structures formation was 
inhibited after Bozepinib treatment at these doses (Fig. 
2A).
In order to evaluate the effects of Bozepinib on 
cell migration, we performed a wound healing assay on 
SKBR-3 breast and HCT-116 colon cancer cell lines. 
Data showed a significant dose-dependent cell migration 
inhibition after 48h of treatment with 0.2, 2 and 5 µM of 
Bozepinib compared to mock-treated cells (Fig. 2C and 
2D). The known Interferon alpha (IFN) anti-proliferative 
agent has been included as a control [20].
Bozepinib treatment induces genome-wide gene 
expression changes in breast cancer cells
To understand the molecular changes underlying 
Bozepinib exposure we performed a microarray assay 
comparing the effect of 5 µM in MDA-MB 468 cells at 
4 and 16h post-treatment. After 4h of treatment, from 178 
genes differentially expressed (cut-off values >1.5 fold 
change and p<0.05), 115 genes were up-regulated whereas 
64 genes were down-regulated. At 16h, about 471 genes 
were differentially expressed, with 143 up-regulated and 
328 down-regulated (Fig. 3 and Supplementary Tables S4-
7). We observed the down-regulation of genes involved in 
breast cancer tumorigenesis (BRCA1, DKK1, CLAUDIN1), 
Table 1: Bozepinib shows broad anti-proliferative effects and significantly improved 
the therapeutic index (TI).
Cell lines Tissue Bozepinib IC50 (µM) TI 
MCF-7a Breast cancer 0,355 ± 0,011 5,14
MDA-MB 231a Breast cancer 0,166 ± 0,063 11
MDA-MB 468 Breast cancer 0,850 ± 0,003 2,14
SKBR-3 Breast cancer 0,330 ± 0,003 5,53
MCF-10Aa Normal breast 1,825 ± 0,003 NDb 
Caco-2 Colon cancer 0,631 ± 0,008 3,18
T-84 Colon cancer 1,019 ± 0,281 1,97
HT-29 Colon cancer 1,352 ± 0,281 1,48
SW-480 Colon cancer 0,235 ± 0,011 8,56
HCT-116 Colon cancer 0,570 ± 0,020 3,52
CCD-18Co Normal colon 2,012 ± 0,012 NDb 
IC50 was determined based on sulforhodamine-B assay. The data are means ± SEM of 
three independent experiment. aTaken from Ref. [17]. bND=Not determined 
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Figure 1: Western blot and densitometric analysis of different proteins related with cancer cell proliferation after 
treatment with 5 µM of Bozepinib. p-HER2, HER-2, p-AKT, AKT, VEGF, p-JNK and p-ERK1/2 were analyzed after 2, 4, 8 and 16 
h post-treatment in breast cancer cell lines SKBR-3 (A), MCF-7 (B) MDA-MB 468 (C) and the normal mammary epithelial cell line MCF-
10A (D) and their respective mock-treated cells. β-ACTIN was used as housekeeping protein. Western blot quantification was normalized 
with β-ACTIN signal and relative to mock-treated cells (value 1). Data were obtained from three independent experiments performed in 
duplicate and are expressed as mean ± SD (**P < 0.01 vs control; *P < 0.05 vs control).
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Figure 2: Capillary network formation and cell migration assays. (A) Representative light microscopy analysis of cells at 
different culture stages and HUVEC grown on Matrigel™ coated wells with EGM-2 medium. Pictures were taken at 4 and 8 hours after 
0 µM (Mock), 0,01 µM, 0,1 µM and 5 µM treatment with Bozepinib. Pictures from one representative experiment of three independent 
experiments are shown. Scale bar = 2.00 μm (left panel). Semi-quantification of the tube formation index. Bars correspond to the percentage 
of the number of capillary-like structures compared with the controls (HUVEC), measured after 24 hours of culture on Matrigel™. All data 
from three independent experiments performed in duplicate are expressed as mean ± SD (** P < 0.05 vs HUVEC) (right panel). (B) Cell 
viability (left panel) and apoptosis (right panel) of HUVEC cells were measured at 4 and 8 hours after 0 µM (Mock), 0,01 µM, 0,1 µM and 
5 µM treatment with Bozepinib. (C) Wound-healing assays were performed at 0 and 48 h in SKBR-3 and HCT-116 cells in mock-treated 
cells (0 µM), cells treated with 0,2 µM, 2 µM and 5 µM of Bozepinib. Pictures were taken with a phase-contrast microscope (10×). 100 IU/
ml of Interferon alpha (IFN) was used as an antiproliferative control. (D) The wound closure was illustrated by showing the area covered 
by cells 48 hours after wounding. The panel represents the quantification of the wound closure area calculated by measuring the diminution 
of the wound bed surface upon time using Image J software 1.47v (http://imagej.nih.gov/ij) in SKBR-3 and HCT-116 cells.
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Figure 3: Gene expression profiling of MDA-MB 468 Bozepinib-treated breast cancer cells. (A) Heat map of the 50 top fold 
change gene up and down-regulated at 4 and 16 hours. (B) Gene clusters pathways affected by Bozepinib-treatment after 4 hours and 16 
hours. Microarrays data were processed by DAVID, KEGG, BIOCARTA, PANTHER and REACTOME. 
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Figure 4: IPA pathway analysis of MDA-MB 468 cells treated with Bozepinib. (A) IPA networks in MDA-MB 468 cancer 
cell line generated with microarray data gene. Networks were classified as breast cancer, metastasis and invasive mixed breast carcinoma 
at 4 hours of treatment and as inflammatory response at 16 hours of treatment. Discontinuous lines are related with indirect interaction. (B) 
Validation by real-time RT-PCR of up- and down-regulated related cancer genes in MDA-MB 468 after treatment with Bozepinib for 4 and 
16h obtained from microarray analysis compared with mock-treated cells (value 1) and normalized with GAPDH reporter gene. Data were 
obtained from three independent experiments performed in duplicate and are expressed as mean ± SD (** P < 0.01vs control).
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Figure 5: Effects of Bozepinib on ALDH subpopulations. (A) Antiproliferative activities for Bozepinib and Salinomycin 
against subpopulations ALDH +/- and “No Sorter” cells from breast SKBR-3 and MDA-MB-468 and colon HCT-116 cell lines. (B) Anti-
proliferative activity of Bozepinib on sphere formation of ALDH+, ALDH- and “No Sorter” cells from HCT-116 colon cell line at 1, 5 
and 20 µM concentrations, compared with mock-treated cells. (C) Number of spheres counted in different sizes from HCT-116 ALDH+, 
ALDH- and “No Sorter” subpopulations. The data are from a representative experiment performed in duplicate wells. (D) Apoptosis 
level of ALDH+/- subpopulations from SKBR-3 and HCT-116 cell lines were determined using the Annexin V-fluorescein isothiocyanate 
detection kit after 24 hours of mock-treatment or treatment with the IC50 and twice the IC50 concentration of Bozepinib. All data from 
three independent experiments performed in duplicate are expressed as mean ± SD (**P < 0.01 vs mock-treated cells; *P < 0.05 vs mock-
treated cells). (E) Western blot analysis of c-MYC and β-CATENIN in ALDH+ and ALDH- subpopulations isolated from SKBR-3 cells, 
and (F) GLI-3, SOX-2, c-MYC, β-CATENIN in ALDH+ and ALDH- subpopulations isolated from HCT-116 cells after mock-treatment 
and Bozepinib-treatment with IC50 and 2×IC50 concentration for 24 hours. Relative western blot quantification of proteins normalized 
with β-ACTIN signal and relative to mock-treated cells (value 1) in ALDH+ and ALDH- subpopulations. Data were obtained from three 
independent experiments performed in duplicate and are expressed as mean ± SD (** P < 0.01 vs control, *P < 0.05 vs control). 
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tumor cell progression (NOTCH3, MAML2, VIMENTIN), 
multidrug resistance (VTRNA1-1), cell cycle progression 
(E2F8A), DNA reparation (BRCA1), metastasis 
(VIMENTIN, BRMS1L) and the up-regulation of genes 
involved in the inhibition of angiogenesis (CXCL10), 
apoptosis (CASP4), repressor of metastasis (BRMS1L) 
or genes involved in cell proliferation inhibition (CSE), 
among others (Fig. 3A). 
The gene list was then subdivided into functional 
categories by term enrichment score with DAVID 
bioinformatic analysis. A summary of functional gene 
clusters is shown in Fig. 3B. In addition the IPA system 
was used to generate networks of molecular relationships 
between different genes (the cut-off log ratio was set at 
1.5) (Fig. 4A). We subsequently validated the microarray 
results in MDA-MB 468 cells using qRT-PCR. As shown 
in Fig. 4B, CSE and CXCL10 were up-regulated while 
MAML2, E2F8A, NOTCH3 and CLAUDIN1 were down-
regulated in MDA-MB 468 cells.
Bozepinib has cytotoxicity against CSCs 
subpopulations and inhibits the expression of 
CSCs-related proteins
We determined the cytotoxic effect of Bozepinib 
on SKBR-3 and MDA-MB 468 breast and HCT-116 
colon CSCs enriched subpopulations by growing them 
into low attachment plates with sphere forming medium 
for 72h. After that, CSCs were separated using ALDH 
activity by FACS (Supplementary Fig. S1). IC50 values 
were determined in both ALDH positive cells (called 
ALDH+), ALDH negative cells (called ALDH-) and in 
cells growing in sphere forming medium without sorter 
enrichment process (called No Sorter). Moreover, we used 
Salinomycin as reference of a potent anti-CSCs drug [21]. 
As shown in Fig. 5A, Bozepinib showed an IC50 range in 
SKBR-3 and MDA-MB 468 cells around that displayed 
by Salinomycin. Moreover, our compound was able to 
considerably reduce the number and size of spheres at 
5 µM and to abolish the sphere-formation ability after 
treatment with 20 µM (Fig. 5B and 5C).
Next, we analyzed the apoptosis levels induced 
by Bozepinib in ALDH+/- subpopulations, showing that 
Bozepinib was able to induce a significant level of cell 
death by apoptosis in the resistant ALDH + subpopulations 
from both SKBR-3 and HCT-116 cell lines. Higher levels 
of apoptosis were detected in the ALDH- subpopulations 
(Fig. 5D).
Finally, we determined the modification of several 
described proteins involved in the stem cell phenotype 
of these subpopulations such as GLI-3, SOX-2, c-MYC 
and β-CATENIN. For this aim, both ALDH+ and ALDH- 
SKBR-3 breast and HCT-116 colon cancer subpopulations 
were treated with the IC50 and twice the IC50 of Bozepinib 
values for 24 hours. The c-MYC oncoprotein was 
detected in both SKBR-3 and HCT-116 cell lines with 
a high level of expression in ALDH+ subpopulations in 
comparison with the ALDH- subpopulations. Bozepinib 
induced a significant reduction of c-MYC level in ALDH+ 
HCT-116 cells and, interestingly, was able to inhibit its 
expression in ALDH+ SKBR-3-treated cells and in 
ALDH- subpopulations of both HCT-116 and SKBR-3 
cells (Fig. 5E and 5F). The same trend was obtained for 
β-CATENIN expression where Bozepinib reduced its level 
in ALDH+ SKBR3 subpopulation. However, β-CATENIN 
was not expressed in ALDH- SKBR-3 cells. In addition, 
our compound was able to reduce β-CATENIN expression 
in ALDH+ HCT-116 subpopulation and to inhibit them in 
ALDH- HCT-116 cells (Fig. 5E and 5F).
GLI-3, a described inhibitor of stem cell properties 
[22] was detected in ALDH- HCT-116 cells and was 
absent in the ALDH+ HCT-116 subpopulations. After 
the Bozepinib treatment GLI-3 was strongly induced in 
both subpopulations. However, no changes at protein 
level were detected in ALDH+/- subpopulations isolated 
from the SKBR-3 cell line (data not shown). The stem 
cell transcription factor SOX2 was detected in HCT-116 
ALDH+ subpopulation but was reduced after treatment 
with IC50 and practically disappeared after treatment with 
2×IC50 of Bozepinib. In HCT-116 ALDH- subpopulation 
the expression of SOX2 protein was very weak (Fig. 5E 
and 5F). 
Bozepinib inhibits growth and metastasis of 
tumor xenografts in nude mice without induction 
of sub-acute toxicity 
We have previously reported that Bozepinib has 
no acute toxicity in BALB/c mice even at the highest 
i.p. bolus dose of 200 mg/kg and p.o. bolus dose of 
50 mg/kg after 2 weeks [17]. In the present work we 
decided to evaluate the sub-acute toxicity after 29 days 
of i.p. treatment with 100 mg/kg twice a week, showing 
that Bozepinib-treated mice presented no weight loss 
or unusual behavior (Supplementary Fig. S2A) and the 
histopathologic examination did not find any detectable 
toxicity in the liver or kidneys (data not shown). These 
data indicate that, at the concentration used, Bozepinib did 
not cause any systemic damage.
To evaluate the effect of Bozepinib on tumour 
growth, heterotopic tumour xenografts were established 
using the MDA-MB 468 breast cancer cell line and the HT-
29 colon cancer cell line. Nine days later, tumors reached 
a size superior to 100 mm3, and the mice received an i.p. 
injection of 25 mg/kg of Bozepinib or methylcellulose 1%, 
respectively. Bozepinib treatment significantly inhibited 
colon and breast cancer tumor growth when compared 
with control group (P < 0.01, n = 12). From day 3 for HT-
29 cell line and day 18 for MDA-MB 468 after Bozepinib 
injection, the average of tumor volume was significantly 
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Figure 6: In vivo antitumor activity of Bozepinib. (A) In vivo determination of Bozepinib anti-tumor activity in MDA-MB 468 breast 
cancer cells. Mock-treated mice with vehicle alone (n= 8) and treated with Bozepinib (25mg/kg, n=8). (B) Representative hematoxylin and 
eosin (H&E)-stained sections of tumors in mice mock-treated (10×) and treated with Bozepinib (4×) and representative H&E-stained lung 
section from a metastasic nodule (10×) in mock-treated mice and Bozepinib-treated mice (20×).
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lower in comparison with control group (Fig. 6A-B and 
Supplementary Figure S2B). Inmunohistochemistry 
analysis showed that primary breast cancer tumours had a 
different morphological appearance between mice mock-
treated and treated with Bozepinib. Control group had a 
significant cell number indicative of a highly proliferative 
tissue; however, mice treated with Bozepinib displayed 
small size of tumors and with necrotic and non-viable 
tumor areas (Fig. 6B). The moderate ability of MDA-
MB 468 cells to form metastasis in nude mice has been 
described [23]. We were able to detect lung metastasis in 
5 of 6 (83.3%) mice in the control group (Fig. 6B) and, 
surprisingly, only 1 out of 6 mice (16.6%) treated with 
Bozepinib presented a lung metastasis. The antimigratory 
effect of Bozepinib together these in vivo results suggest 
the potential of Bozepinib also as an anti-metastatic 
compound.
DISCUSSION
Identification and characterization of new 
pharmacological activities from novel drugs represent an 
effective way of accelerating the translation of discoveries 
from bench to clinical applications. Previously, we have 
identified Bozepinib as a potent anti-tumor compound 
against breast and colon cancer cells [17, 18, 24] . 
Although we described the role of protein kinase PKR 
as a target of Bozepinib involved in the apoptosis of 
breast and colon cancer cells [18], here we have made a 
profound study of the mechanism of action of this drug. 
We demonstrated the selective effect of Bozepinib that 
exhibited high TI in both breast and colon cancer cells, 
and we identified interesting signaling pathways involved 
in its efficacy.
Bozepinib was a selective inhibitor of HER2 
positive breast cancer cells as we demonstrated by the 
kinase assay, also verified with immunoblot analysis in the 
HER2 positive SKBR-3 breast cancer cell line, and in the 
xenotrasplant of HER 2 positive HT-29 colon cancer cells 
[25] in nude mice. Approximately, 25-30% of all primary 
breast tumors over-express the HER2 receptor, which is 
associated with a poor prognosis and an overall survival 
decrease in patients [5]. Trastuzumab, is actually used in 
first line clinical treatment for metastatic HER2 positive 
breast tumors, showing an overall survival improvement 
in patients. However, a considerable percentage of 
patients with metastatic disease ultimately develop 
resistance to trastuzumab [26], which increases the need 
of developing novel targeted therapies that overcome 
treatment resistance. In this way it is important to target 
not only the proliferating related receptors but also 
downstream signaling proteins involved in this process. 
In fact, current therapies are based on the combinations of 
different drugs with the aim to target both HER2 receptor 
and downstream signaling pathways such as tyrosine 
kinase inhibitors and mTOR inhibitors among others 
[27]. Bozepinib also presented an inhibitory effect over 
AKT, JNK, ERKs and VEGF signaling pathways. AKT 
is an important part of PI3K signaling and its activation 
is involved in tumor progression through increased cell 
proliferation, invasion and angiogenesis [28]. More 
investigation is necessary in order to determine if the 
inhibition of AKT phosphorylation induced by Bozepinib 
would be involved in the down-regulation of constitutively 
active PI3K/Akt/mTOR. Whereas an inhibition on EGFR 
activity was detected by the kinome assay, we were not 
able to detect changes in the phosphorylation of the 
receptor in EGFR positive MDA-MB 468 cells treated 
with EGF and Bozepinib (data not shown). However, we 
detected inhibition in the JNK and ERKs phosphorylation 
in both MCF-7 cells described as negative for EGFR 
expression and in MDA-MB 468 cells expressing high 
EGFR levels [29]. ERK inhibitors are currently considered 
as a therapeutic option for the treatment of patients who 
relapse on BRAF or MEK inhibitor therapy [30]. The 
selective effect of Bozepinib over tumors expressing 
these mutations opens a new via to be investigated with 
this novel drug. The therapeutic effect of JNK inhibitors 
has been described as proliferation suppressors with anti-
tumor consequences and, in fact, several JNK inhibitors 
are currently in preclinical stages [31, 32]. Our data 
suggest that Bozepinib is a selective inhibitor of HER2 
signaling, but its anti-tumor activity on breast and colon 
cancer cells lines expressing different receptors patterns 
suggests several mechanisms of action for this compound. 
The inhibition of proliferative signaling usually 
converges in the inhibition of angiogenesis and cell 
migration [31]. In fact, Bozepinib was able to reduce the 
VEGF basal level detected in the SKBR-3 cancer cells and 
showed inhibitory effects against VEGFR-1, VEGFR-2 
and VEGFR-3 in the kinome assay. In accordance with the 
anti-angiogenic properties and the inhibition of migration 
presented by Bozepinib in cancer cell lines, the metastatic 
capacity of MDA-MB 468 cells xenotransplanted in nude 
mice was also inhibited after i.p. treatment, suggesting the 
clinical potential of this promising anti-tumor drug.
The modulation of pathways involved in 
tumorigenesis by Bozepinib was also evident in the gene-
profiling assays carried out by microarrays analysis in 
breast cancer-treated cells at different times. The data 
obtained suggest numerous mechanisms that could be 
involved in the anti-tumor activity of this compound. 
Bozepinib treatment up-regulated several genes involved 
in metabolic routes, such as cytochrome p450 family 
genes and glutathione metabolism related genes. Both 
routes are not only involved in the metabolism of drugs 
but also in anti-tumor processes such as detoxification, 
stress response, apoptosis and proliferation [33, 34]. 
Moreover, the gene expression of Cysthiathionine-Lyase 
CSE, an enzyme with anti-proliferative properties that 
engages ERKs and JNK signaling [35], was up-regulated 
after Bozepinib treatment. In addition, we found the up-
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regulation of genes as the chemokine CXCL10, involved in 
immune and inflammatory processes and that posses anti-
angiogenic activity, which are associated with increased 
immune infiltration and improved survival in patients 
with solid malignancies including breast cancer [36, 
37]. On the other hand, genes involved in breast cancer 
tumorigenesis such as CLAUDIN1 and E2F8 among 
others, were down-regulated after Bozepinib-treatment. It 
has been previously suggested that CLAUDIN 1 acts as 
a tumor suppressor. However, recent studies have shown 
that this protein participates directly in promoting breast 
cancer progression, possibly through the alteration of the 
expression of epithelial-mesenchymal transition genes, 
and actually its down-regulation has been described as a 
contribution to the inhibition of breast cancer migration 
[38]. The deregulation of the E2F family member of 
transcription factors including the E2F8 atypical member, 
contributes to oncogenesis and progression. Ectopic 
over-expression of E2F8 promoted cell proliferation, 
colony formation and tumorigenicity, whereas the E2F8 
knockdown inhibited these phenotypes [39] suggesting 
that the down-regulation of E2F8 induced by Bozepinib 
could contribute to its anti-tumor effect. Moreover, it 
has recently been shown that HER2 tumorigenesis and 
metastasis are regulated by E2F activator transcription 
factors [40]. 
Surprisingly, Bozepinib induced the down-
regulation of important genes involved in Notch and Wnt 
signaling. These genes contribute to the CSC phenotype 
when they are de-regulated [41]. We detected a down-
regulation of the co-activator Mastermind-like MAML-
2 protein, which decreases Notch signaling reducing 
the primary tumor sphere formation and side population 
in MCF-7 cell line, contributing to the decrease in the 
number of CSC subpopulations [42]. We also found an 
evident down-regulation of the NOTCH 3 gene, which 
has recently been involved in the proliferation of both 
HER2 positive and negative breast cancer cells, suggesting 
that targeted suppression of this signaling pathway may 
be a promising strategy for the treatment of determined 
HER2-related breast cancers [43, 44]. According to the 
proteomic and genomic results obtained after Bozepinib 
treatment and considering the recent works relating 
HER2 positivity with CSC phenotype in breast cancer 
cells with high ALDH activity [45, 46], we decided to 
analyze the efficacy of Bozepinib over CSCs enriched 
subpopulations. Since there is controversy about the 
efficacy of sphere-forming cultures to select CSCs [47, 
48] we used ALDH activity to enrich cell cultures with 
clonal ability and stem-like properties. Moreover, previous 
to the treatment with Bozepinib the in vivo tumorigenic 
potential of ALDH+ and the reestablishment of tumor 
heterogeneity was demonstrated (data not shown). Our 
results showed that Bozepinib inhibited both mamo- and 
colono-spheres formation in subpopulations isolated 
by ALDH activity. High ALDH activity is associated 
with metastasis, resistance to chemotherapies and poor 
prognosis in human cancers, and it has been identified as 
one of the most specific markers of human CSCs [49]. 
Moreover, Bozepinib was able to induce apoptosis in the 
resistant ALDH + subpopulations from both SKBR-3 
and HCT-116 cells, although in less degree that the more 
sensible ALDH– subpopulations. CSCs are apoptosis 
resistant in order to secure the production of progeny 
[50] and an apoptosis program is a prerequisite for any 
tumor-initiating cell and may support the survival of 
CSCs in response to chemo- or radio-therapy. Therefore, 
targeted therapies reactivating death program and inducing 
apoptosis in CSCs may synergize with established 
therapies and increase efficacy in the clinic. In addition, 
Bozepinib displayed IC50 values in a similar range to 
Salinomycin, which has been described as a selective 
and potent drug against CSCs with limited use in human 
due to considerable toxicity [21]. Interestingly, we 
detected a significant reduction in the level of c-MYC 
and β-CATENIN in both breast and colon ALDH+ and 
ALDH- cells after Bozepinib treatment. Although most of 
these proteins are expressed in normal and differentiated 
tumor cells, it has been described that the expression level 
of determined genes involved in stem-like properties 
determines the CSCs process [51]. In accordance with the 
high level of stem signaling proteins described for CSCs, 
we detected higher levels of these proteins in the ALDH+ 
subpopulations in comparison with ALDH- cells. Recently, 
it has been reported the cooperation between c-MYC and 
HER2 and between c-MYC and β-CATENIN to drive 
mammary stem cell amplification and tumorigenesis 
[10, 12]. In fact, the down-regulation of c-MYC triggers 
the inhibition of cancer cell proliferation, invasion and 
migration [52]. Wnt/β-catenin signaling plays a critical 
role in CSCs, being β-CATENIN a key mediator of Wnt 
signaling [53]. Moreover, whereas no detectable levels 
of SOX2 protein were present in breast cancer cells, we 
detected a considerable level of SOX2 in ALDH-isolated 
colon cancer cells that was significantly reduced after 
Bozepinib treatment. The transcription factor SOX2 is 
involved together with c-MYC, KLF4 and OCT3/4 in the 
induction and maintenance of pluripotent stem cells and 
has been also associated the expression of both SOX2 
and β-CATENIN with metastases and poor prognosis 
in colon cancer [15]. Finally, we detected significant 
changes in GLI-3 expression in colon cancer cells, a 
described target gene transcription repressor of Hedgehog 
signaling pathway [22]. Whereas GLI-3 expression was 
detected in ALDH- HCT-116 isolated cells, this protein 
was not detected in the ALDH+ cells, suggesting that 
the Hedgehog signaling pathway is involved in the CSC 
phenotype as has been previously described [22]. The 
treatment with Bozepinib induced a strong expression of 
GLI-3 protein level in both ALDH+ and ALDH- colon 
cancer cells. In addition, according to reported data [54], 
in our study, the activation of GLI-3 protein corresponded 
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with an inactivation of β-CATENIN expression in CSCs 
subpopulations after Bozepinib treatment. Since GLI-
3 over-expression reduced tumor cell proliferation and 
induced apoptosis in colon CSCs [55], the GLI-3 induction 
by Bozepinib could be one of the mechanisms by which 
this drug exerts its anti-tumor activity in colon CSCs that 
must be deeply explored. 
Although we show promising data proving the 
efficacy of Bozepinib over CSCs, the mechanism by 
which Bozepinib inhibits the CSC growth requires 
further detailed investigation. The Bozepinib effect 
involves different pathways and kinases as we described 
in a previous work showing the role of the PKR pro-
apoptotic kinase [18], and in the present study by the 
inhibition of proliferative signaling pathways. However, 
the determination of the impact of every kinase or 
every signaling pathway of the drug is not yet known 
and probably it is a pleiotropic effect that finally leads 
to its effectiveness. Moreover, the specific HER2, JNK 
and ERKs inhibition, the anti-angiogenic and anti-
migration activity together with the in vivo anti-tumor 
and anti-metastatic effect and the non-systemic toxicity 
of Bozepinib, encourage further studies on the therapeutic 






(Bozepinib) was synthesized as previously described 
[17], dissolved in DMSO and stored at -20 ºC. For each 
experiment, the stock solutions were further diluted in 
medium to obtain the desired concentrations. The final 
solvent concentration in cell culture was ≤ 0.1% v/v of 
DMSO, a concentration without effect on cell replication. 
Parallel cultures of cells in medium with DMSO were used 
as controls.
Cell lines 
The four human breast cancer cell lines MCF-7, 
MDA-MB-468, MDA-MB 231, SKBR-3 and the five 
human colon cancer cell lines Caco-2, T-84, HT-29, SW-
480, HCT-116 were obtained from American Type Culture 
Collection (ATCC) and maintained in Dulbecco’s Modified 
Eagle Medium (DMEM; Sigma-Aldrich) supplemented 
with 10% FBS. Non-tumoral cell lines MCF-10A (breast) 
and CCD-18Co (colon) obtained from ATCC were 
cultured in DMEM/F12 medium supplemented with 5% 
horse serum (HS), 0.5 µg/ml hydrocortisone, 0.02 µg/
ml epithelial growth factor (EGF), 0.01 µg/ml insulin 
and 100ng/ml cholera toxin. HUVEC were cultured in 
endothelial growth medium (EGM-2; Lonza). All cell 
lines listed above were tested for authentication using the 
short-tandem repeat profiling and were passaged for less 
than 6 months, and routinely assayed for mycoplasma 
contamination.
In vitro cytotoxicity assays 
The effect of anticancer drugs on cell viability was 
assessed using the sulforhodamine-B colorimetric assay. 
Briefly, cells (1×103 cells/well) were seeded onto 24-
well plates and incubated for 24 h and then treated with 
different Bozepinib concentrations. Three days later, wells 
were aspirated, fresh medium and drug were added, and 
cells were maintained for 3 additional days. Cells were 
maintained with the drug for six days. Thereafter, cells 
were processed as previously described [56], using a 
Titertek Multiscan apparatus (Flow, Irvine, California) at 
492 nm. We evaluated the linearity of the SRB assay with 
a cell number for each cell line before every cell growth 
experiment. The IC50 values were calculated from semi-
logarithmic dose-response curves by linear interpolation. 
All of the experiments were plated in triplicate wells and 
were carried out at least twice.
Kinase inhibition assays 
The kinase inhibition profile of Bozepinib 
was determined using a panel of 36 protein kinases 
(Supplementary Table S1). Residual activity values were 
measured by testing each compound at two concentrations 
(5×10-5 M and 5×10-6 M) in singlicate for each kinase 
assay. Detailed methods for kinome analyses are provided 
in Supplementary Materials and Methods.
MTS cell viability assay
Enriched subpopulations of CSCs were seeded 
in a concentration of 3000 cells/well in 96-well plates 
in sphere forming medium and treated with different 
Bozepinib concentrations. After 72 h, 10 μl of CellTiter 
96® AQueous One Solution Cell Proliferation Assay, 
MTS (10 mg/ml) (Promega Corporation, Madison, USA) 
was added to each well and incubated at 37°C for 2-4 h. 
Plates were read at 570 nm on a Bio-Rad plate reader.
Apoptosis analysis
Cells were plated in six-well plates and after 
treatment were trypsinized and analyzed using an 
Annexin V-fluorescein isothiocyanate detection kit 
(eBioscience Inc., San Diego, CA, USA). The samples 
were immediately processed using a FACSAria III flow 
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cytometer (Becton Dickinson, BD Biosciences, Franklin 
Lakes, NJ, USA) from the Scientific Instrumental Center 
(University of Granada).
Western blotting
For attached cell lines, cells were seeded on 6-well 
plates in their respective medium. After treatment, 
medium was removed from attached cells and floating 
CSCs spheres were centrifugated at 1500 rpm, washed 
twice with PBS and then lysed in Laemmli buffer. 
Immunoblotting on whole cell lysates was performed 
following routine protocols [18]. All antibodies used for 
western blot analysis are listed in the Supplementary 
Material and Methods.
Functional capillary formation assays 
The ability of Bozepinib to inhibit capillaries in 
semisolid medium was tested in HUVEC using a Matrigel 
assay (see Supplementary Material and Methods).
Wound-healing assay
Breast and colon cancer cells were seeded in 6-well 
plates and grown to 80% confluence. Wounds were created 
by scraping monolayer cells with a 200 µl (for HCT-116) 
and 1000 µl (for SKBR-3) pipette tip, and non-adherent 
cells were washed off with medium. At 0, 24 and 48 h after 
the creation of wounds, Bozepinib-treated and control 
non-treated cells were observed and photographed with 
a 10× objective in a phase-contrast microscopy. Wound 
distances were measured at each time point and expressed 
as the average percent of wound closure by comparing 
the zero time. Image-Pro Plus 6.0 software was used to 
quantify the wound area. All experiments were plated in 
triplicate wells and were carried out at least three times.
Microarray analysis
MDA-MB 468 cells were treated with 5 µM 
Bozepinib for 4 h and 16 h. No treated cells were used 
as control. Total RNAs were extracted using Quiagen 
extraction Kit, according to the manufacturer’s protocol. 
RNA microarray analyses were carried out with the 
Affymetrix Human Gene 1.0 ST arrays according to the 
Affymetrix standard protocol. The gene list with x-fold 
cut-off was then subdivided into functional categories 
with the bioinformatic analysis resource DAVID (NCI, 
Frederick, http://david.abcc.ncifcrf.gov). Gene pathway 
analysis was also conducted by DAVID and Ingenuity 
Pathways Analysis (IPA, https://www.ingenuity.com/).
Quantitative real time RT-PCR
Total RNA from the different cell lines was extracted 
from duplicate 80% confluent cultures using the TRIZOL 
reagent following the instructions of the manufacturer 
(Life Technologies). cDNA was synthesized by reverse 
transcrition of total RNA using the Reverse Transcription 
System (Promega) and qRT-PCR assay was done using 
SYBR Green PCR Master Mix (Promega) and random 
primers. Each reaction was performed in triplicate from 
two cDNA dilutions. The comparative threshold cycle (Ct) 
method was used to calculate the amplification factor as 
specified by the manufacturer. Human GADPH was used 
as an internal standard to normalize variations in RNA 
quality in the quantities of input cDNA. The amount of 
target and endogenous reference was determined from a 
standard curve for each experimental sample. The standard 
curve was constructed by 5-fold serial dilutions of cDNA 
from 1 μg. Primer sequences are listed in Supplementary 
Table S2.
Isolation of CSCs
Cancer stem-like cells from SKBR-3 breast and 
HCT-116 colon cancer cells lines were isolated using 
the ALDEFLUOR assay (StemCell Technologies) 
by fluorescence-activated cell sorting (FACS) (see 
Supplementary Material and Methods) and enriched 
subpopulation of CSCs were grown with a specific sphere-
forming medium in ultralow attachment plates (Corning) 
as previously described [49].
In vivo sub-acute toxicity and anti-tumor 
xenograft studies
Sub-acute toxicity was determined in six weeks 
old BALBC/c female (n=20) during 29 days. Bozepinib 
dissolved in methylcellulose 1% was administered in 
a single i.p. bolus injection at 100 mg/kg twice a week. 
Control mice were (n=10) inoculated with the same 
volume of methylcellulose. Mice were maintained under 
standard conditions and for each treatment schedule, were 
weighed and assessed twice weekly for systemic toxicity 
(listlessness, weight loss) and local toxicity (alopecia, skin 
reaction, and leg motility). 
To establish xenograft tumors six- to eight-
week old female BALB/c nude mice (Charles Rives 
Laboratories) were used. All procedures were approved 
by the Institutional Animal Care and Use Committee 
at the University of Granada. They were housed and 
maintained at 20°C to 24°C, 50% RH, a 14 to 10 h light-
dark cycle with food and water ad libitum. The HT-29 and 
MDA-MB 468 tumors were generated by subcutaneous 
injections of 2×106 cells/mouse using 26-gauge needles. 
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Tumors were allowed to grow to an average volume of 
100 mm3. Animals (n= 8 per group) were then randomly 
assigned as control and treatment groups and treated 
with methylcellulose 1% (control vehicle) or Bozepinib 
(25 mg/kg, dissolved in methylcellulose 1%) injected 
i.p. three times a week for 45 days for MDA-MB 468 
and two weeks for HT-29. Tumor weight was calculated 
according to the formula: TW (mg) = tumor volume (mm3) 
= d2 × D/2, where d and D are the shortest and longest 
diameters, respectively. Paraffin-embedded blocks of all 
tumors were sectioned at 5 μm. Each sample was stained 
with hematoxylin and eosin (H&E) for histopathologic 
analysis. 
Statistical analysis
Data are presented as mean ± SD. Differences 
between groups for each sample were tested by one-
way ANOVA. Assumptions of analysis of variance 
(homocedesticity and normality) were tested and assured 
by using transformed data sets [log (dependent variable 
value 1] when necessary. Significance was accepted at P 
< 0.05 in all cases.
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